Tianzhu atomized solution treats rats with chronic pharyngitis through the TRPV1 and TLR2-MyD88-NF-κB pathways
Objective This study aims to investigate the molecular mechanism of Tianzhu Atomized Solution (TZWHY) in treating chronic pharyngitis (CP). We used an in vivo rat model to elucidate this mechanism. Methods A bacterial chronic pharyngitis model was established,and different doses of TZWHY were administered via aerosol treatment to evaluate its anti-inflammatory effects. LC-MS was used for component analysis of the medication. ELISA was employed to measure serum levels of IL-6,IL-1β,and TNF-α,real-time PCR was used to detect TLR2 mRNA expression,and Western blot was used to analyze the expression of MyD88,NF-κB p-p65,and TRPV1 proteins. Results The CP model showed that TZWHY effectively alleviated symptoms in rats. ELISA results indicated that TZWHY significantly reduced the elevated serum levels of IL-6,IL-1β,and TNF-α. Western blot and qPCR results demonstrated that TZWHY decreased the elevated levels of NF-κB p65,MyD88,TLR2,and TRPV1 in pharyngeal mucosal tissues. Conclusion This study explored and confirmed the therapeutic mechanism of TZWHY in treating CP through rat experiments. The results suggest that TZWHY may treat chronic pharyngitis by regulating the TRPV1 pathway and the TLR2-MyD88-NF-κB pathway.
万方数据
维普
